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Materials. Between February 2004 and June 2012, 68 eligible patients were recruited. The criteria for poor-risk rectal cancer were
tumors with circumferential resection margin threatened, T4 tumors, and N2 tumors. Patients received high dose neoadjuvant
radiotherapy with a median dose of 59.4Gy with a concomitant ﬂuoropyrimidine based chemotherapy. Surgery was planned 6-8
weeks after CRT. The primary objective was local control; secondary objectives were resection (R) status, pathologic response,
overall survival (OS), metastatic progression free survival (MPFS) and toxicity.
Results. At a median follow-up of 29.5 months (6.9–81.7), local control rate was 94.1%. Sixty-four patients (94.2%) proceeded to
surgery, and two of them receives surgery combined to 8Gy intra-operative radiation therapy. 58 patients had R0 resection, 4
patients had R1 resection and 2 patients had R2 resection. Four patients remained inoperable. Pathologic complete response
(pCR) was observed in 9 patients (13.2%), and in additional 40 patients had downstaging (58.8%). The MPFS after 1 and 3 years
were 83% and 45.3% and the OS 1- and 3-year survivals were 95.4% and 61.6%, respectively. Adjuvant chemotherapy was not
associated with a signiﬁcantly improvement of OS in good responders (pCR, pT0-2). RCT was well tolerated, with only one grade
3 (1.2%) gastrointestinal toxicity (diarrhea). Main grade I toxicities were proctitis (36.8%), diarrhea (32.4%), and anemia (26.5%).
Conclusions. High dose neoadjuvant radiochemotherapy in poor-risk rectal cancer is associated with improved tumor resectability
and allow to increase the local control without an increase in acute toxicity.
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Introduction. Although surgery remains the main treatment for rectal cancer, neoadjuvant radiotherapy is the standard treatment
in patients with locally advanced stage. Improving radiotherapy treatments should result in a better local control without higher
toxicity proﬁles.
Purpose. The purpose of this study is to determine whether or not dose scalation translates into higher complete pathological
response. We also analyze other pathological derived prognostic factors, metastatic disease rate and patient’s survival.
Methods. Study of 68 patients with rectal adenocarcinoma, T3-4 N+ treated with neoadjuvant radio-chemotherapy. All patients
received IMRT and most of them concomitant Capecitabine. Radiotherapy treatments were administered with Oncor Expression
LINAC (Siemens®), planning system used was XIO 4.62 (CMS®). IGRT was performed with cone-beam in all patients. Surgery was
performed 6–8 weeks after treatment in all patients.
Results. Sixty-seven patients (98.6%) completed IMRT treatment, 28 patients received a 2Gy/day equivalent dose lower than
55Gy and 40 received a 2Gy/day equivalent dose higher than 55Gy G-III (CTCAE v3.0) acute toxicity was gastrointestinal (10.3%),
genitourinary (5.9%), skin (1,5%). Sphincter sparring surgery was performed in 53 patients (78%). Mean distance from anal verge
to tumor at diagnosis was 7.47 cm (1–15 cm). Twenty patients achieve complete pathological response (29.4%), in 17 additional
patients (25%) there was grade 3 regression (Rödel scale). Radial margin was free of inﬁltration in 91.2% of anatomical pieces.
After 40 months follow-up no local recurrence was found, 10 patients (14.7%) have developed distant metastasis. Forty months
estimated overall survival is 94.7%.
Conclusions. Dose escalation IMRT for rectal cancer in our experience is safe and achieves high rates of complete pathological
responses. Tumor free radial margin, demonstrated as good prognostic factor, was also achieved in 91.2% of the patients.
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Introduction. There is a tendency to perform MRI after concomitant radiotherapy and chemotherapy in rectal carcinoma, to assess
response before surgery.
Objectives. To determinate the predictive value MRI pre-surgery in rectal carcinoma after pre-surgery concomitant radiotherapy
and chemotherapy (RTQT).
Material and method. Since June 2011 until December 2012, we included 26 patients who were treated with neoadjuvant RTQT
and had pre-surgery MRI. Chemotherapy 5-FU continue infusion treatment was in 74% patients during radiotherapy and 22.2%
patients oral capecitabine. The radiotherapy scheme was 45Gy over pelvis and 50.4Gy over rectum plus margin. This scheme was
in 88.6%patients and the rest of themwere treatedwith other radiotherapy schemes. After treatment, the patientswere evaluated
with pelvic MRI before surgery and we obtained the T and N. We have compared this T and N (Tr and Nr) with histopathologic
ﬁndings.
Results. We used the weighted kappa index to evaluate concordance grade between Tr vs pathologic T (Tp) and Nr vs pathologic
N (Np). The kappa index was 0.17 (IC 95%: −0.06 to 0.41) to Tr vs Tp and =.16 (IC 95%: 0.11 to 0.57) to Nr and Np. Both results were
not signiﬁcant with p 0.11 and p 0.23 respectively.
